Search

Your search keyword '"Katarey, Dev"' showing total 119 results
Start Over Author "Katarey, Dev"
119 results on '"Katarey, Dev"'

2. Regional variation in characteristics of patients with decompensated cirrhosis admitted to hospitals in the UK

Author

Tavabie, Oliver D, primary, Abeysekera, Kushala WM, additional, Brennan, Paul N, additional, Marjot, Thomas, additional, Kronsten, Victoria T, additional, Li, Wenhao, additional, Nayagam, Jeremy S, additional, Dhaliwal, Amritpal, additional, Hardy, Tim, additional, Maurice, James B, additional, Zakeri, Nekisa, additional, Abbas, Nadir, additional, Abbasi, Abdullah, additional, Abbott, Jane, additional, Abdul, Rahman, additional, Abdulaziz, Mohamed, additional, Abduljabbar, Duaa, additional, Adamson, Robbie, additional, Adebayo, Danielle, additional, Adhikarla, Aditya Kumar, additional, Adler, Maciej, additional, Afifi, Mostafa, additional, Ahmad, Salman, additional, Ahmed, Shayan, additional, Aithal, Guruprasad, additional, Akram, Ali, additional, Al Radhi, Balqees, additional, Al-Talib, Ismaeel, additional, Alele, Jolomi, additional, Ali, Alaa Mohammed, additional, Almusai, Safa, additional, Appleby, Victoria, additional, Asmat, Huma, additional, Astbury, Sarah, additional, Atkinson, Ali, additional, Badrulhisham, Fakhirah, additional, Balachandrakumar, Vinay K, additional, Ball, Alexandra, additional, Banfa, Moses, additional, Barn, Jeevan, additional, Begum, Shahnaz, additional, Belfield, Katherine, additional, Bendall, Oliver, additional, Bennett, Kris, additional, Bernal, William, additional, Bhandari, Rajan, additional, Bhatti, Prashan, additional, Bradley, Meg, additional, Brown, Edward, additional, Bryce, Kathleen, additional, Buchanan, Ryan, additional, Burke, Laura, additional, Campbell, Roisin, additional, Cargill, Tamsin, additional, Carroll, Geraldine, additional, Cartledge, James, additional, Chatterjee, Devnandan, additional, Chaundry, Rayan, additional, Choudhry, Zeshan, additional, Clare, Kathleen, additional, Cobbold, Jeremy, additional, Coburn, Robert, additional, Cook, Charlotte, additional, Corvan, Fintan, additional, Cox, Rebecca, additional, Craig, Darren, additional, Creamer, John, additional, Curran, Christopher, additional, De Silva, Shanika, additional, Dean, Laurence, additional, Dillon, Jayne, additional, Dillon, John, additional, Dunn, Rebecca, additional, Eckersley, Robert, additional, Eike, Gidveig, additional, Elagib, Amul, additional, Elkholi, Ayman, additional, Elshaarawy, Omar, additional, Faloon, Sarah, additional, Fan, Francis, additional, Fazili, Mohammad, additional, Fernandes, Denzil, additional, Fox, James, additional, Foxton, Matthew, additional, Gaba, Waqas, additional, Gaikwad, Girish, additional, Gairola, Abishek, additional, Galanakis, Vasileios, additional, Gallaher, Charles, additional, Gautam, Nisham, additional, Germain, Lewis, additional, Giles, Ben, additional, Gill, Ceri, additional, Glover, Ben, additional, Glover, John, additional, Gomez, David, additional, Gomez, Michael, additional, Gordon, Victoria, additional, Gormley, Sarah, additional, Goulder, John, additional, Goyal, Simran, additional, Greenham, Olivia, additional, Guthrie, Sarah, additional, Hackett, Richard, additional, Haddadin, Yazan, additional, Hadjinicolaou, Andreas, additional, Hall, Jonathan, additional, Hamza, Mohammed, additional, Haque, Tasnuma, additional, Harris, Rebecca, additional, Hart, Catherine, additional, Hasan, Sundas, additional, Hasnain Nadir, Syed Mujtaba, additional, Hassall, James, additional, Hawker-Bond, George, additional, Hawkyard, Jake, additional, Healey, Scott, additional, Hogan, Brian, additional, Hornby, Catherine, additional, Humayun, MD, additional, Hutchison, John, additional, Iftikhar, Zahra, additional, Ismail, Asem, additional, James, Joel, additional, Jones, Rebecca, additional, Jopson, Laura, additional, Juthani, Dipal, additional, Kaina, Philippa, additional, Karim, Aadil, additional, Karim, Syed Misbah, additional, Kashyap, Vaishnavi, additional, Kassab, Mohamed, additional, Katarey, Dev, additional, Kenny, Lee, additional, Kerry, Georgina, additional, Khan, Adnan, additional, Khan, Ayesha, additional, Khan, Azab, additional, Khan, Muhammad Taha, additional, Khan, Tahir, additional, Khatib, Aseil, additional, Khattak, Mohammad Fawad, additional, King, Ji Jade, additional, Kooner, Emily, additional, Korani, Mohammed, additional, Kotha, Sreelakshmi, additional, Lam, Wai Liam, additional, Lateef, Mohammed, additional, Leighton, Jess, additional, Leith, Damien, additional, Liaros, Angela, additional, Liu Yin, James, additional, Lourenco, Floyd, additional, Lyles, Annabel, additional, Macken, Lucia, additional, Magee, Ciaran, additional, Maggs, Daniel, additional, Mahalingam, Aarani, additional, Mahenthiran, Midusa, additional, Mahmood, Rizwan, additional, Mandour, Mandour Omer, additional, Manocha, Namita, additional, Mansour, Dina, additional, Marks, Daniella, additional, Martin, Ciara, additional, Martin, Harry, additional, Martin, Iana, additional, Martin, Katherine, additional, Maruthan, Sachan, additional, Masin, Rhys, additional, Mason, Denise, additional, Matthews, Charmaine, additional, Mavrou, Athina, additional, Maxan, Ema, additional, Maxfield, Dominic, additional, McAvoy, Emma, additional, McCaughan, Hannah, additional, McColl, Kirsty, additional, McCorry, Roger, additional, McDonald, Stewart, additional, McDowell, Hannah, additional, McGoran, John, additional, McIlwane, Stewart, additional, McPherson, Stuart, additional, Meakin, Olivia, additional, Mebarek, Leila, additional, Merrill, Hannah, additional, Michail, Stephanie, additional, Modarres, Pedram, additional, Mohamedali, Alaa, additional, Mohammed, Yaser, additional, Mohammed, Zakiuddin, additional, Mohan, Jaiganesh, additional, Monnier, Chloe, additional, Moran, Eilis, additional, Moroni, Francesca, additional, Morrison, Gary, additional, Msaddi, Anas, additional, Mutar, Sarah, additional, Nahed, Ismail, additional, Navaratnam, Janardhan, additional, Neto-Pereira, Luis, additional, Ng, Jennifer, additional, Nwoguh, Chinonso, additional, O'Kane, Rebecca, additional, Omar, Sohail, additional, Ososanya, Abosede, additional, Parambil, Jessiya Veliyankodan, additional, Patel, Jay, additional, Pericleous, Marinos, additional, Pervais, Zeshan, additional, Phoolchund, Anju, additional, Pietrzycki, Julian, additional, Pillay, Lushen, additional, Pohl, Keith, additional, Prabhu, Kiran, additional, Putri, Yesita Rizky F., additional, Qazi, Umang, additional, Rafique, Khizar Khalid, additional, Raghuraman, Arun, additional, Raman, Krithivasan, additional, Ranade, Vaishali, additional, Rastelli, Francesca, additional, Ratcliffe, Elizabeth, additional, Rattehalli, Deepa, additional, Raza, Tufail, additional, Razak, Amir, additional, Read, George, additional, Robins, Anne, additional, Rowe, Ian, additional, Rushbrook, Simon, additional, Salama, Mohamed, additional, Saravan, Ramasamy, additional, Sarkar, Srishti, additional, Saunsbury, Emma, additional, Scott, Jennifer, additional, Serna, Solange, additional, Shahzad, Hassnain, additional, Shamsaldeen, Mohammed, additional, Sharip, Mohammed, additional, Shearer, Jessica, additional, Sheikh, Adam, additional, Sheiybani, Giovanna, additional, Sherwin, Michelle, additional, Sheth, Abhishek, additional, Shintre, Nidhi, additional, Singhal, Saket, additional, Sinha, Rohit, additional, Sinharay, Ricky, additional, Smith, Gloria, additional, Smith, Ria, additional, Snowdon, Victoria, additional, Spicer, Joanne, additional, Spoor, Johannes, additional, Sreenivasan, Shiva, additional, Srinivasa, Amar, additional, Srivastava, Ankur, additional, St. Aimee, Louise, additional, Stagg, Georgia, additional, Stanley, Jatinder, additional, Stevenson, Jason, additional, Stokes, Daniel, additional, Stroud, Robert, additional, Subhani, Mohsan, additional, Suliman, Hiba, additional, Sultana, Marium, additional, Summers, Nikki, additional, Sutherland, Chloe, additional, Swann, Rachael, additional, Sykes, Lynne, additional, Taha, Mostafa, additional, Tan, Kwei Eng, additional, Tariq, Zohaib, additional, Tay, Joshua Jun Ming, additional, Taylor, Alison, additional, Thakor, Amit, additional, Tsang, James, additional, Turner, Lucy, additional, Tyler, Zaccharie, additional, Unitt, Esther, additional, Volcek, Edward, additional, Watson, Iona, additional, Watters, Chris, additional, Wells, Gemma, additional, White, Helen, additional, Widlak, Monika, additional, Williams, Matthew, additional, Wischhusen, Jack, additional, Woodland, Hazel, additional, Wren, Louise, additional, Xyda, Souzana, additional, Yeh, Julian, additional, Young, Alison, additional, and Yuan, Jack Shie Jie, additional

Published
2023
Full Text
View/download PDF

3. Location and allocation

Author

Artzner, Thierry, Bernal, William, Belli, Luca S, Conti, Sara, Cortesi, Paolo A, Sacleux, Sophie‐Caroline, Pageaux, George‐Philippe, Radenne, Sylvie, Trebicka, Jonel, Fernandez, Javier, Perricone, Giovanni, Piano, Salvatore, Nadalin, Silvio, Morelli, Maria C, Martini, Silvia, Polak, Wojciech G, Zieniewicz, Krzysztof, Toso, Christian, Berenguer, Marina, Iegri, Claudia, Invernizzi, Federica, Volpes, Riccardo, Karam, Vincent, Adam, René, Faitot, François, Rabinowich, Liane, Saliba, Faouzi, Meunier, Lucy, Lesurtel, Mickael, Uschner, Frank E, Michard, Baptiste, Coilly, Audrey, Meszaros, Magdalena, Poinsot, Domitille, Besch, Camille, Schnitzbauer, Andreas, De Carlis, Luciano G, Fumagalli, Roberto, Angeli, Paolo, Arroyo, Vincente, Fondevila, Constantino, Duvoux, Christophe, Jalan, Rajiv, Viganò, Raffaella, Mazzarelli, Chiara, Lauterio, Andrea, Giacomoni, Alessandro, Donato, Francesca, Lampertico, Pietro, Pasulo, Luisa, Fagiuoli, Stefano, Colledan, Michele, Cristina Morelli, Maria, Vitale, Giovanni, Ottobrelli, Antonio, Patrono, Damiano, Romagnoli, Renato, Petridis, Ioannis, Cillo, Umberto, Germani, Giacomo, Burra, Patrizia, Bachellier, Philippe, Schneider, Francis, Castelain, Vincent, Addeo, Pietro, Deridder, Mathilde, Caroline Sacleux Audrey Coilly, Sophie, Faouzi, Saliba, Adam, Rene, Samuel, Didier, Guichon, Celine, Faure, Stéfanie, Ursic‐Bedoya, Josè, Fondevila, Costantino, Colmenero, Jorde, Toapanta, David, Hernández‐Tejero, María, Vinaixa, Carmen, Polak, Wojciech G., den Hoed, Caroline, Haan, Jubi E., Della Penna, Andrea, Erhard Uschner, Frank, Welker, Martin, Zeuzem, Stefan, Bechstein, Wolf, Goossens, Nicolas, Raszeja‐Wyszomirska, Joanna, Rabinovich, Liane, Katarey, Dev, Agarwal, Banwari, Surgery, Gastroenterology & Hepatology, Intensive Care, Biomatériaux et Bioingénierie (BB), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Interface de Recherche Fondamentale et Appliquée en Cancérologie (IRFAC - Inserm U1113), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC)-Fédération de Médecine Translationelle de Strasbourg (FMTS), Mitochondrie, stress oxydant et protection musculaire (MSP), Université de Strasbourg (UNISTRA), the ELITA/EF-CLIF Working Group, Artzner, T, Bernal, W, Belli, L, Conti, S, Cortesi, P, Sacleux, S, Pageaux, G, Radenne, S, Trebicka, J, Fernandez, J, Perricone, G, Piano, S, Nadalin, S, Morelli, M, Martini, S, Polak, W, Zieniewicz, K, Toso, C, Berenguer, M, Iegri, C, Invernizzi, F, Volpes, R, Karam, V, Adam, R, Faitot, F, Rabinowich, L, Saliba, F, Meunier, L, Lesurtel, M, Uschner, F, Michard, B, Coilly, A, Meszaros, M, Poinsot, D, Besch, C, Schnitzbauer, A, De Carlis, L, Fumagalli, R, Angeli, P, Arroyo, V, Fondevila, C, Duvoux, C, Jalan, R, Viganò, R, Mazzarelli, C, Lauterio, A, Giacomoni, A, Donato, F, Lampertico, P, Pasulo, L, Fagiuoli, S, Colledan, M, Cristina Morelli, M, Vitale, G, Ottobrelli, A, Patrono, D, Romagnoli, R, Petridis, I, Cillo, U, Germani, G, Burra, P, Bachellier, P, Schneider, F, Castelain, V, Addeo, P, Deridder, M, Caroline Sacleux Audrey Coilly, S, Faouzi, S, Samuel, D, Guichon, C, Faure, S, Ursic‐bedoya, J, Colmenero, J, Toapanta, D, Hernández‐tejero, M, Vinaixa, C, den Hoed, C, Haan, J, Della Penna, A, Erhard Uschner, F, Welker, M, Zeuzem, S, Bechstein, W, Goossens, N, Raszeja‐wyszomirska, J, Rabinovich, L, Katarey, D, and Agarwal, B

Subjects
Transplantation, ILL CIRRHOTIC-PATIENTS, Liver transplantation, Hepatology, Intensive care, Waiting list, Surgery, Acute-on-Chronic Liver Failure, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

There is growing evidence that liver transplantation (LT) is the most effective treatment for acute-on-chronic liver failure grade-3 (ACLF-3). This study examines whether and how this evidence translates into practice by analyzing the variability in intensive care unit (ICU) admissions, listing strategies, and LT activity for patients with ACLF-3 across transplantation centers in Europe. Consecutive patients who were admitted to the ICU with ACLF-3, whether or not they were listed and/or transplanted with ACLF-3, between 2018 and 2019 were included across 20 transplantation centers. A total of 351 patients with ACLF-3 were included: 33 had been listed prior to developing ACLF-3 and 318 had not been listed at the time of admission to the ICU. There was no correlation between the number of unlisted patients with ACLF-3 admitted to the ICU and the number listed or transplanted while in ACLF-3 across centers. By contrast, there was a correlation between the number of patients listed and the number transplanted while in ACLF-3. About 21% of patients who were listed while in ACLF-3 died on the waiting list or were delisted. The percentage of LT for patients with ACLF-3 varied from 0% to 29% for those transplanted with decompensated cirrhosis across centers (average = 8%), with an I(2) index of 68% (95% confidence interval, 49%-80%), showing substantial heterogeneity among centers. The 1-year survival for all patients with ACLF-3 was significantly higher in centers that listed and transplanted more patients with ACLF-3 (>10 patients) than in centers that listed and transplanted fewer: 36% versus 20%, respectively (p = 0.012). Patients with ACLF-3 face inequity of access to LT across Europe. Waitlisting strategies for patients with ACLF-3 influence their access to LT and, ultimately, their survival.

Published
2022

4. Nonviral Liver Disease Burden in People Living With HIV and Elevated Transaminases: A Cross-Sectional Study.

Author

Katarey, Dev, Tan, Yishi, Mourad, Adele, Potts, Jonathan R., Vickers, Laura, Beksinska, Alicja, Sharp, Harriet, Parnell, Bethany, Gilleece, Yvonne, and Verma, Sumita

Abstract

Introduction: Because of improved life expectancy in people living with HIV (PLWH), liver disease is increasingly being recognized. We assessed nonviral chronic liver disease burden in PLWH. Methods: The HIV non-virAL liver disease study (2014–2021) prospectively recruited PLWH with elevated serum alanine aminotransferase levels and negative hepatitis serology. Clinically significant hepatic fibrosis (CSHF) was defined as liver stiffness measurement of >7.1 kPa and hazardous alcohol use as Alcohol Use Disorders Identification Test score ≥ 8. Primary outcome was prevalence/predictors of CSHF. Results: Total recruited were n = 274, 92% male, median age 52 (45–59) years, and 96% having undetectable HIV viral load. Overall, n = 97 (35%) had hazardous alcohol use, n = 72 (26%) had metabolic syndrome, and 17%–27% had exposure to hepatotoxic antiretrovirals. Prevalence of CSHF was 20% (n = 54), prevalence of cirrhosis (liver stiffness measurement > 12.5 kPa) being 7% (19/274). Risk factors for CSHF were hazardous alcohol use in 44% (n = 24), metabolic syndrome in 46% (n = 25), and hepatotoxic antiretrovirals in 56% (n = 30), most having more than one risk factor. Independent predictors of CSHF were serum high-density lipoprotein (odds ratio [OR] 0.220; 95% confidence interval [CI]: 0.061 to 0.790, P = 0.020) (inverse relationship); serum aspartate aminotransferase (OR 1.033, 95% CI: 1.001 to 1.067, P = 0.045), and didanosine use (OR 2.878, 95% CI: 1.228 to 6.774, P = 0.015). Moderate–severe hepatic steatosis was identified in 52% (n = 142). FIB-4 and aspartate aminotransferase-to-platelet ratio index performed poorly in predicting CSHF (positive predictive value 27.3% and 30.6%, respectively) and advanced fibrosis (≥F3) (positive predictive value 17.6% and 5.9%, respectively). Conclusion: In this study, 20% of PLWH had CSHF associated with high prevalence of hazardous alcohol use/metabolic syndrome/potentially hepatotoxic antiretrovirals. These potentially modifiable risk factors need addressing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis

Author

Tavabie, Oliver D., Abbott, Jane, Abeysekera, Kushala WM., Balachandrakumar, Vinay K., Bennett, Kris, Brennan, Paul, Buchanan, Ryan, Dhaliwal, Amritpal, Galanakis, Vasileios, Hardy, Tim, Harris, Rebecca, Kronsten, Victoria T., Leighton, Jess, Li, Wenhao, Yin, James Liu, Macken, Lucia, Marjot, Thomas, Maurice, James B., McDowell, Hannah, Navaratnam, Janardhan, Pohl, Keith, Nayagam, Jeremy S., Saunsbury, Emma, Scott, Jennifer, Sheth, Abhishek, Sinharay, Ricky, Sheiybani, Giovanna, Subhani, Mohsan, Turner, Lucy, White, Helen, Zakeri, Nekisa, Cook, Charlotte, Abbas, Nadir, Abbasi, Abdullah, Abdul, Rahman, Abdulaziz, Mohamed, Abduljabbar, Duaa, Adamson, Robbie, Adebayo, Danielle, Adhikarla, Aditya Kumar, Adler, Maciej, Ahmad, Salman, Ahmed, Shayan, Afifi, Mostafa, Akram, Ali, Al Radhi, Balqees, Al-Talib, Ismaeel, Alele, Jolomi, Ali, Alaa Mohammed, Almusai, Safa, Appleby, Victoria, Asmat, Huma, Astbury, Sarah, Atkinson, Ali, Badrulhisham, Fakhirah, Ball, Alexandra, Banfa, Moses, Barn, Jeevan, Begum, Shahnaz, Belfield, Katherine, Bendall, Oliver, Bhandari, Rajan, Bhatti, Prashan, Bradley, Meg, Brown, Edward, Bryce, Kathleen, Burke, Laura, Campbell, Roisin, Cargill, Tamsin, Carroll, Geraldine, Cartledge, James, Chatterjee, Devnandan, Chaundry, Rayan, Choudhry, Zeshan, Clare, Kathleen, Cobbold, Jeremy, Coburn, Robert, Corvan, Fintan, Cox, Rebecca, Craig, Darren, Creamer, John, Curran, Christopher, De Silva, Shanika, Dean, Laurence, Dillon, Jayne, Dunn, Rebecca, Eckersley, Robert, Eike, Gidveig, Elagib, Amul, Elkholi, Ayman, Elshaarawy, Omar, Faloon, Sarah, Fan, Francis, Fazili, Mohammad, Fernandes, Denzil, Fox, James, Foxton, Matthew, Gaba, Waqas, Gaikwad, Girish, Gairola, Abishek, Gallaher, Charles, Gautam, Nisham, Germain, Lewis, Giles, Ben, Gill, Ceri, Glover, Ben, Glover, John, Gomez, David, Gomez, Michael, Gordon, Victoria, Gormley, Sarah, Goulder, John, Goyal, Simran, Greenham, Olivia, Guthrie, Sarah, Hackett, Richard, Haddadin, Yazan, Hadjinicolaou, Andreas, Hall, Jonathan, Haque, Tasnuma, Hart, Catherine, Hasnain Nadir, Syed Mujtaba, Hassall, James, Hasan, Sundas, Hawker-Bond, George, Hawkyard, Jake, Healey, Scott, Hornby, Catherine, Hamza, Mohammed, Humayun, M.D., Hutchison, John, Iftikhar, Zahra, Ismail, Asem, James, Joel, Jopson, Laura, Juthani, Dipal, Kaina, Philippa, Karim, Aadil, Karim, Syed Misbah, Kashyap, Vaishnavi, Kassab, Mohamed, Katarey, Dev, Kenny, Lee, Kerry, Georgina, Khan, Adnan, Khan, Ayesha, Khan, Azab, Khan, Muhammad Taha, Khan, Tahir, Khatib, Aseil, Khattak, Mohammad Fawad, King, Ji Jade, Korani, Mohammed, Kotha, Sreelakshmi, Kooner, Emily, Lam, Wai Liam, Lateef, Mohammed, Leith, Damien, Liaros, Angela, Lourenco, Floyd, Lyles, Annabel, Mahenthiran, Midusa, Magee, Ciaran, Maggs, Daniel, Mahalingam, Aarani, Mahmood, Rizwan, Mandour, Mandour Omer, Manocha, Namita, Mansour, Dina, Marks, Daniella, Martin, Ciara, Martin, Harry, Martin, Iana, Martin, Katherine, Maruthan, Sachan, Masin, Rhys, Mason, Denise, Matthews, Charmaine, Mavrou, Athina, Maxan, Ema, Maxfield, Dominic, McAvoy, Emma, McColl, Kirsty, McCaughan, Hannah, McCorry, Roger, McGoran, John, McDonald, Stewart, McIlwane, Stewart, Meakin, Olivia, Mebarek, Leila, Merrill, Hannah, Michail, Stephanie, Modarres, Pedram, Mohamedali, Alaa, Mohammed, Yaser, Mohammed, Zakiuddin, Mohan, Jaiganesh, Monnier, Chloe, Moran, Eilis, Morrison, Gary, Moroni, Francesca, Msaddi, Anas, Mutar, Sarah, Neto-Pereira, Luis, Nahed, Ismail, Ng, Jennifer, Nwoguh, Chinonso, O’Kane, Rebecca, Omar, Sohail, Ososanya, Abosede, Parambil, Jessiya Veliyankodan, Patel, Jay, Pericleous, Marinos, Pervais, Zeshan, Phoolchund, Anju, Pietrzycki, Julian, Pillay, Lushen, Prabhu, Kiran, Putri, Yesita Rizky F., Qazi, Umang, Rafique, Khizar Khalid, Raman, Krithivasan, Ranade, Vaishali, Rastelli, Francesca, Ratcliffe, Elizabeth, Rattehalli, Deepa, Raza, Tufail, Razak, Amir, Raghuraman, Arun, Read, George, Robins, Anne, Rushbrook, Simon, Salama, Mohamed, St. Aimee, Louise, Saravan, Ramasamy, Sarkar, Srishti, Serna, Solange, Shahzad, Hassnain, Shamsaldeen, Mohammed, Sharip, Mohammed, Shearer, Jessica, Sheikh, Adam, Sherwin, Michelle, Shintre, Nidhi, Singhal, Saket, Sinha, Rohit, Smith, Gloria, Smith, Ria, Spicer, Joanne, Spoor, Johannes, Sreenivasan, Shiva, Srinivasa, Amar, Srivastava, Ankur, Stagg, Georgia, Stanley, Jatinder, Stevenson, Jason, Stokes, Daniel, Stroud, Robert, Suliman, Hiba, Sultana, Marium, Summers, Nikki, Sutherland, Chloe, Swann, Rachael, Sykes, Lynne, Taha, Mostafa, Tan, Kwei Eng, Tariq, Zohaib, Ming Tay, Joshua Jun, Taylor, Alison, Thakor, Amit, Tsang, James, Tyler, Zaccharie, Unitt, Esther, Volcek, Edward, Wischhusen, Jack, Watson, Iona, Watters, Chris, Wells, Gemma, Widlak, Monika, Williams, Matthew, Woodland, Hazel, Wren, Louise, Xyda, Souzana, Yeh, Julian, Young, Alison, Jie Yuan, Jack Shie, Aithal, Guruprasad, Bernal, William, Dillon, John, Hogan, Brian, McPherson, Stuart, Jones, Rebecca, Rowe, Ian, and Snowdon, Victoria

Published
2023
Full Text
View/download PDF

8. Location and allocation: inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe

Author

Artzner, T, Bernal, W, Belli, L, Conti, S, Cortesi, P, Sacleux, S, Pageaux, G, Radenne, S, Trebicka, J, Fernandez, J, Perricone, G, Piano, S, Nadalin, S, Morelli, M, Martini, S, Polak, W, Zieniewicz, K, Toso, C, Berenguer, M, Iegri, C, Invernizzi, F, Volpes, R, Karam, V, Adam, R, Faitot, F, Rabinowich, L, Saliba, F, Meunier, L, Lesurtel, M, Uschner, F, Michard, B, Coilly, A, Meszaros, M, Poinsot, D, Besch, C, Schnitzbauer, A, De Carlis, L, Fumagalli, R, Angeli, P, Arroyo, V, Fondevila, C, Duvoux, C, Jalan, R, Viganò, R, Mazzarelli, C, Lauterio, A, Giacomoni, A, Donato, F, Lampertico, P, Pasulo, L, Fagiuoli, S, Colledan, M, Cristina Morelli, M, Vitale, G, Ottobrelli, A, Patrono, D, Romagnoli, R, Petridis, I, Cillo, U, Germani, G, Burra, P, Bachellier, P, Schneider, F, Castelain, V, Addeo, P, Deridder, M, Caroline Sacleux Audrey Coilly, S, Faouzi, S, Samuel, D, Guichon, C, Faure, S, Ursic‐bedoya, J, Colmenero, J, Toapanta, D, Hernández‐tejero, M, Vinaixa, C, den Hoed, C, Haan, J, Della Penna, A, Erhard Uschner, F, Welker, M, Zeuzem, S, Bechstein, W, Goossens, N, Raszeja‐wyszomirska, J, Rabinovich, L, Katarey, D, Agarwal, B, Artzner, Thierry, Bernal, William, Belli, Luca S, Conti, Sara, Cortesi, Paolo A, Sacleux, Sophie‐Caroline, Pageaux, George‐Philippe, Radenne, Sylvie, Trebicka, Jonel, Fernandez, Javier, Perricone, Giovanni, Piano, Salvatore, Nadalin, Silvio, Morelli, Maria C, Martini, Silvia, Polak, Wojciech G, Zieniewicz, Krzysztof, Toso, Christian, Berenguer, Marina, Iegri, Claudia, Invernizzi, Federica, Volpes, Riccardo, Karam, Vincent, Adam, René, Faitot, François, Rabinowich, Liane, Saliba, Faouzi, Meunier, Lucy, Lesurtel, Mickael, Uschner, Frank E, Michard, Baptiste, Coilly, Audrey, Meszaros, Magdalena, Poinsot, Domitille, Besch, Camille, Schnitzbauer, Andreas, De Carlis, Luciano G, Fumagalli, Roberto, Angeli, Paolo, Arroyo, Vincente, Fondevila, Constantino, Duvoux, Christophe, Jalan, Rajiv, Viganò, Raffaella, Mazzarelli, Chiara, Lauterio, Andrea, Giacomoni, Alessandro, Donato, Francesca, Lampertico, Pietro, Pasulo, Luisa, Fagiuoli, Stefano, Colledan, Michele, Cristina Morelli, Maria, Vitale, Giovanni, Ottobrelli, Antonio, Patrono, Damiano, Romagnoli, Renato, Petridis, Ioannis, Cillo, Umberto, Germani, Giacomo, Burra, Patrizia, Bachellier, Philippe, Schneider, Francis, Castelain, Vincent, Addeo, Pietro, Deridder, Mathilde, Caroline Sacleux Audrey Coilly, Sophie, Faouzi, Saliba, Adam, Rene, Samuel, Didier, Guichon, Celine, Faure, Stéfanie, Ursic‐Bedoya, Josè, Fondevila, Costantino, Colmenero, Jorde, Toapanta, David, Hernández‐Tejero, María, Vinaixa, Carmen, Polak, Wojciech G., den Hoed, Caroline, Haan, Jubi E., Della Penna, Andrea, Erhard Uschner, Frank, Welker, Martin, Zeuzem, Stefan, Bechstein, Wolf, Goossens, Nicolas, Raszeja‐Wyszomirska, Joanna, Rabinovich, Liane, Katarey, Dev, Agarwal, Banwari, Artzner, T, Bernal, W, Belli, L, Conti, S, Cortesi, P, Sacleux, S, Pageaux, G, Radenne, S, Trebicka, J, Fernandez, J, Perricone, G, Piano, S, Nadalin, S, Morelli, M, Martini, S, Polak, W, Zieniewicz, K, Toso, C, Berenguer, M, Iegri, C, Invernizzi, F, Volpes, R, Karam, V, Adam, R, Faitot, F, Rabinowich, L, Saliba, F, Meunier, L, Lesurtel, M, Uschner, F, Michard, B, Coilly, A, Meszaros, M, Poinsot, D, Besch, C, Schnitzbauer, A, De Carlis, L, Fumagalli, R, Angeli, P, Arroyo, V, Fondevila, C, Duvoux, C, Jalan, R, Viganò, R, Mazzarelli, C, Lauterio, A, Giacomoni, A, Donato, F, Lampertico, P, Pasulo, L, Fagiuoli, S, Colledan, M, Cristina Morelli, M, Vitale, G, Ottobrelli, A, Patrono, D, Romagnoli, R, Petridis, I, Cillo, U, Germani, G, Burra, P, Bachellier, P, Schneider, F, Castelain, V, Addeo, P, Deridder, M, Caroline Sacleux Audrey Coilly, S, Faouzi, S, Samuel, D, Guichon, C, Faure, S, Ursic‐bedoya, J, Colmenero, J, Toapanta, D, Hernández‐tejero, M, Vinaixa, C, den Hoed, C, Haan, J, Della Penna, A, Erhard Uschner, F, Welker, M, Zeuzem, S, Bechstein, W, Goossens, N, Raszeja‐wyszomirska, J, Rabinovich, L, Katarey, D, Agarwal, B, Artzner, Thierry, Bernal, William, Belli, Luca S, Conti, Sara, Cortesi, Paolo A, Sacleux, Sophie‐Caroline, Pageaux, George‐Philippe, Radenne, Sylvie, Trebicka, Jonel, Fernandez, Javier, Perricone, Giovanni, Piano, Salvatore, Nadalin, Silvio, Morelli, Maria C, Martini, Silvia, Polak, Wojciech G, Zieniewicz, Krzysztof, Toso, Christian, Berenguer, Marina, Iegri, Claudia, Invernizzi, Federica, Volpes, Riccardo, Karam, Vincent, Adam, René, Faitot, François, Rabinowich, Liane, Saliba, Faouzi, Meunier, Lucy, Lesurtel, Mickael, Uschner, Frank E, Michard, Baptiste, Coilly, Audrey, Meszaros, Magdalena, Poinsot, Domitille, Besch, Camille, Schnitzbauer, Andreas, De Carlis, Luciano G, Fumagalli, Roberto, Angeli, Paolo, Arroyo, Vincente, Fondevila, Constantino, Duvoux, Christophe, Jalan, Rajiv, Viganò, Raffaella, Mazzarelli, Chiara, Lauterio, Andrea, Giacomoni, Alessandro, Donato, Francesca, Lampertico, Pietro, Pasulo, Luisa, Fagiuoli, Stefano, Colledan, Michele, Cristina Morelli, Maria, Vitale, Giovanni, Ottobrelli, Antonio, Patrono, Damiano, Romagnoli, Renato, Petridis, Ioannis, Cillo, Umberto, Germani, Giacomo, Burra, Patrizia, Bachellier, Philippe, Schneider, Francis, Castelain, Vincent, Addeo, Pietro, Deridder, Mathilde, Caroline Sacleux Audrey Coilly, Sophie, Faouzi, Saliba, Adam, Rene, Samuel, Didier, Guichon, Celine, Faure, Stéfanie, Ursic‐Bedoya, Josè, Fondevila, Costantino, Colmenero, Jorde, Toapanta, David, Hernández‐Tejero, María, Vinaixa, Carmen, Polak, Wojciech G., den Hoed, Caroline, Haan, Jubi E., Della Penna, Andrea, Erhard Uschner, Frank, Welker, Martin, Zeuzem, Stefan, Bechstein, Wolf, Goossens, Nicolas, Raszeja‐Wyszomirska, Joanna, Rabinovich, Liane, Katarey, Dev, and Agarwal, Banwari

Abstract

Background: There is growing evidence that liver transplantation (LT) is the most effective treatment for acute-on-chronic liver failure grade-3 (ACLF-3). This study examines whether and how this evidence translates into practice by analyzing the variability in intensive care unit (ICU) admissions, listing strategies and LT activity for ACLF-3 patients across transplant centers in Europe. Methods: Consecutive patients who were admitted to the ICU with ACLF-3, whether or not they were listed and/or transplanted with ACLF-3 between 2018 and 2019 were included across 20 transplantation centers. Results: 351 patients with ACLF-3 were included: 33 had been listed prior to developing ACLF-3 and 318 had not been listed at the time of admission to the ICU. There was no correlation between the number of unlisted ACLF-3 patients admitted to the ICU and the number listed or transplanted whilst in ACLF-3 across centers. In contrast, there was a correlation between the number of patients listed and the number transplanted whilst in ACLF-3. 21% of patients who were listed whilst in ACLF-3 died on the waiting list or were delisted. The percentage of LT for ACLF-3 patients varied from 0%-29% of patients transplanted with decompensated cirrhosis across centers (average = 8%), with an I2 index of 68% (95% CI: 49%-80%), showing substantial heterogeneity among centers. The one-year survival for all patients with ACLF-3 was significantly higher in centers that listed and transplanted more ACLF-3 patients (>10 patients) than in centers that listed and transplanted fewer: respectively 36% vs. 20%, p = 0.012. Conclusion: Patients with ACLF-3 face inequity of access to LT across Europe. Wait-listing strategies for ACLF-3 patients influence their access to LT and, ultimately, their survival.

Published
2022

9. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

Author

Miller, Charles, primary, Kwok, Hanson, additional, Harrow, Paul, additional, Vega, Roser, additional, Seward, Edward, additional, Mehta, Shameer, additional, Rahman, Farooq, additional, McCartney, Sara, additional, Parisi, Ioanna, additional, Lim, Samuel Hsiang, additional, Sharma, Esha, additional, Samaan, Mark A, additional, Bancil, Aaron, additional, Kok, Klaartje Bel, additional, Shalabi, Ahmed, additional, Johnston, Emma L, additional, Katarey, Dev, additional, Taherzadeh, Nina, additional, Murray, Charles, additional, Sharip, Mohammed Tauseef, additional, Carter, Martyn J, additional, Radhakrishnan, Shiva T, additional, Peake, Simon, additional, Khakoo, Imran, additional, Wahed, Mahmood, additional, Povlsen, Sebastian, additional, Patel, Mehul, additional, DuBois, Patrick, additional, Finkel, Jemima, additional, Onnie, Clive, additional, and Bloom, Stuart, additional

Published
2022
Full Text
View/download PDF

11. Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study

Author

Hashim, Ahmed., primary, Bremner, Stephen, additional, Grove, Jane I., additional, Astbury, Stuart, additional, Mengozzi, Manuela, additional, O’Sullivan, Margaret, additional, Macken, Lucia, additional, Worthley, Tim, additional, Katarey, Dev, additional, Aithal, Guruprasad P., additional, and Verma, Sumita, additional

Published
2021
Full Text
View/download PDF

13. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)

Author

Belli, Luca S., primary, Duvoux, Christophe, additional, Artzner, Thierry, additional, Bernal, William, additional, Conti, Sara, additional, Cortesi, Paolo A., additional, Sacleux, Sophie-Caroline, additional, Pageaux, George-Philippe, additional, Radenne, Sylvie, additional, Trebicka, Jonel, additional, Fernandez, Javier, additional, Perricone, Giovanni, additional, Piano, Salvatore, additional, Nadalin, Silvio, additional, Morelli, Maria C., additional, Martini, Silvia, additional, Polak, Wojciech G., additional, Zieniewicz, Krzysztof, additional, Toso, Christian, additional, Berenguer, Marina, additional, Iegri, Claudia, additional, Invernizzi, Federica, additional, Volpes, Riccardo, additional, Karam, Vincent, additional, Adam, René, additional, Faitot, François, additional, Rabinovich, Liane, additional, Saliba, Faouzi, additional, Meunier, Lucy, additional, Lesurtel, Mickael, additional, Uschner, Frank E., additional, Fondevila, Costantino, additional, Michard, Baptiste, additional, Coilly, Audrey, additional, Meszaros, Magdalena, additional, Poinsot, Domitille, additional, Schnitzbauer, Andreas, additional, De Carlis, Luciano G., additional, Fumagalli, Roberto, additional, Angeli, Paolo, additional, Arroyo, Vincente, additional, Jalan, Rajiv, additional, Belli, Luca S., additional, Viganò, Raffaella, additional, Mazzarelli, Chiara, additional, Lauterio, Andrea, additional, Giacomoni, Alessandro, additional, Donato, Francesca, additional, Lampertico, Pietro, additional, Pasulo, Luisa, additional, Fagiuoli, Stefano, additional, Colledan, Michele, additional, Morelli, Maria Cristina, additional, Vitale, Giovanni, additional, Patrono, Damiano, additional, Romagnoli, Renato, additional, Ottobrelli, Antonio, additional, Petridis, Ioannis, additional, Cillo, Umberto, additional, Germani, Giacomo, additional, Burra, Patrizia, additional, Bachellier, Philippe, additional, Addeo, Pietro, additional, Besch, Camille, additional, Faitot, Francoise, additional, Sacleux, Sophie Caroline, additional, Faouzi, Saliba, additional, Adam, Rene, additional, Samuel, Didier, additional, Guichon, Celine, additional, Faure, Stéfanie, additional, Ursic-Bedoya, Josè, additional, Colmenero, Jorde, additional, Toapanta, David, additional, Hernández-Tejero, María, additional, Vinaixa, Carmen, additional, Hoed, Caroline den, additional, de Haan, Jubi E., additional, Della Penna, Andrea, additional, Uschner, Frank Erhard, additional, Welker, Martin, additional, Zeuzem, Stefan, additional, Bechstein, Wolf, additional, Goossens, Nicolas, additional, Raszeja-Wyszomirska, Joanna, additional, Katarey, Dev, additional, and Agarwal, Banwari, additional

Published
2021
Full Text
View/download PDF

18. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus antiTNF followed by vedolizumab.

Author

Miller, Charles, Kwok, Hanson, Harrow, Paul, Vega, Roser, Seward, Edward, Mehta, Shameer, Rahman, Farooq, McCartney, Sara, Parisi, Ioanna, Lim, Samuel Hsiang, Sharma, Esha, Samaan, Mark A., Bancil, Aaron, Kok, Klaartje Bel, Shalabi, Ahmed, Johnston, Emma L., Katarey, Dev, Taherzadeh, Nina, Murray, Charles, and Sharip, Mohammed Tauseef

Published
2022
Full Text
View/download PDF

20. Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study.

Author

Hashim, Ahmed., Bremner, Stephen, Grove, Jane I., Astbury, Stuart, Mengozzi, Manuela, O'Sullivan, Margaret, Macken, Lucia, Worthley, Tim, Katarey, Dev, Aithal, Guruprasad P., and Verma, Sumita

Subjects
HEPATIC fibrosis, LIVER diseases, LIVER injuries, CHRONIC diseases, ALCOHOLISM
Abstract

Background/aims: Community‐based assessment and management of chronic liver disease (CLD) in people who are homeless (PWAH) remain poorly described. We aimed to determine prevalence/predictors of CLD in PWAH and assess the performance of non‐invasive liver fibrosis and injury markers. Methods: The Vulnerable Adult LIver Disease (VALID) study provided a "one‐stop" liver service based at homeless hostels. Our primary outcome was the prevalence of clinically significant hepatic fibrosis (CSHF; liver stiffness measurement (LSM) ≥8 kPa). Results: Total individuals recruited were 127, mean ± SD age 47 ± 9.4 years, 50% (95% CI 41%‐59%) and 39% (95% CI 31%‐48%) having alcohol dependence and a positive HCV RNA respectively. CSHF was detected in 26% (95% CI 17%‐35%), independent predictors being total alcohol unit/week (OR 1.01, 95% CI 1.00‐1.02, P =.002) and HCV RNA positivity (OR 2.93, 95% CI 1.12‐7.66, P =.029). There was moderate agreement between LSM and Enhanced Liver Fibrosis (ELF) score (kappa 0.536, P <.001) for CSHF as assessed by LSM ≥8 kPa. Those with CSHF had significantly higher levels of IFN‐γ (P =.002), IL‐6 (P =.001), MMP‐2 (P =.006), ccCK‐18 (P <.001) and ELF biomarkers (P <.001), compared to those without CSHF. Service uptake was ≥95%. Direct acting antiviral (DAA) treatment completion was 93% (95% CI 77%‐99%), sustained virological response (SVR) being 83% (95% CI 64%‐94%). Conclusion: There is a significant liver disease burden from HCV and alcohol in PWAH. Non‐invasive liver fibrosis and injury markers can help in identifying such individuals in the community. Despite a challenging cohort, excellent service uptake and high DAA‐based SVRs can be achieved. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Wide variations in liver transplantation (LT) policies across Europe for patients with acute-on-chronic liver failure (ACLF) despite excellent post-LT survival: Results of a CLIF/ELITA collaborative study

Author

Belli, Luca Saverio, primary, Duvoux, Christophe, additional, Perricone, Giovanni, additional, Pageaux, Georges-Philippe, additional, Meszaros, Magdalena, additional, Artzner, Thierry, additional, Michard, Baptiste, additional, Radenne, Sylvie, additional, Céline, Dr. Guichon, additional, Saliba, Faouzi, additional, Sacleux, Sophie-Caroline, additional, Fernández, Javier, additional, Hernandetz, Maria, additional, Angeli, Paolo, additional, Bernal, William, additional, Morelli, Maria Cristina, additional, Martini, Silvia, additional, Trebicka, Jonel, additional, Zieniewicz, Krzysztof, additional, Nadalin, Silvio, additional, Fondevila, Constantino, additional, Polak, Wojciech, additional, Toso, Christian, additional, Invernizzi, Federica, additional, Volpes, Riccardo, additional, Iegri, Claudia, additional, Haym, Marina Berenguer, additional, Cortesi, Paolo, additional, Conti, Sara, additional, Katarey, Dev, additional, Jalan, Rajiv, additional, and Arroyo, Vicente, additional

Published
2020
Full Text
View/download PDF

32. Does regulating the sale of high-strength beer and cider impact hospital admissions with decompensated alcoholrelated liver disease: A retrospective cohort study.

Author

Haddadin, Yazan, Katarey, Dev, Sachdeva, Manavi, Vickers, Laura, Kaur, Ishleen, Hashim, Ahmed, and Verma, Sumita

Subjects
*ALCOHOLIC beverages, *ALCOHOLIC liver diseases, *ALCOHOL drinking, *LENGTH of stay in hospitals, *HOSPITAL admission & discharge, *LONGITUDINAL method, *MEDICAL records, *PATIENTS, *RETROSPECTIVE studies, *SEVERITY of illness index, *ACQUISITION of data methodology, *ODDS ratio, HOSPITAL care evaluation
Abstract

Objective 'Sensible on Strength' (SoS), a local public health initiative, is aimed at reducing high-strength beer and cider availability. The objective of this study was to assess its impact on local hospital admissions with alcohol-related liver disease (ALD) and on drinking behaviour. Design This was a retrospective cohort study in patients admitted with decompensated ALD, 3 years before and 3 years after the introduction of the SoS initiative. Hospital records of 143 index admissions with decompensated ALD were reviewed. Outcomes measures were the severity of liver disease on admission and mortality (inpatient and long-term), and change (if any) in alcohol drinking behaviour. Results Comparing patients admitted in both phases, there were no significant differences in liver prognostic scores, liverrelated complications, length of stay and inpatient/long-term mortality (p>0.05). However, the SoS initiative was associated with a 33% move away from beer and cider consumption (36.3% vs 54.0%; p=0.034), but without a significant change in units of alcohol consumed. The Model for End-stage Liver Disease (MELD) score was the only independent predictor of inpatient mortality (odds ratio 1.25; p=0.025). Conclusion Despite having no apparent impact on the clinical spectrum of local ALD admissions, it is conceivable that longer follow-up is needed to determine the true impact of this initiative. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

36. Baseline neutrophil‐to‐lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis.

Author

Forrest, Ewan H., Storey, Natasha, Sinha, Rohit, Atkinson, Stephen R., Vergis, Nikhil, Richardson, Paul, Masson, Steven, Ryder, Stephen, Thursz, Mark R., Allison, Michael, Fraser, Andrew, Austin, Andrew, McCune, Anne, Dhanda, Ashwin, Katarey, Dev, Potts, Jonathan, Verma, Sumita, Parker, Richard, and Hayes, Peter C.

Subjects
CORTICOSTEROIDS, HEPATITIS, KIDNEY injuries, LOG-rank test, INFECTION
Abstract

Summary: Background: Treating severe alcoholic hepatitis involves the exposure of patients to corticosteroids for 7 days to assess "response". Aim: To assess the prognostic and therapeutic implications of baseline neutrophil‐to‐lymphocyte ratio (NLR) in patients with severe alcoholic hepatitis. Methods: Patients recruited to the STOPAH trial and an independent validation group were analysed retrospectively. Area under the receiver operating curve (AUC) analysis was performed. Kaplan‐Meier analysis was used to assess survival. Log‐rank test and odds ratio (OR) were used for comparative analysis. Results: Baseline NLR was available for 789 STOPAH patients. The AUC for NLR was modest for 90‐day outcome (0.660), but was associated with infection, acute kidney injury (AKI) and severity of alcoholic hepatitis. Ninety‐day survival was not affected by prednisolone treatment if NLR < 5 or > 8 but mortality was reduced with prednisolone treatment when the NLR was 5‐8 (21.0% cf. 34.5%; P = 0.012). Prednisolone treatment increased the chance of Lille response if the NLR was  ≥ 5 (56.5% cf. 41.1%: P = 0.01; OR 1.86) but increased the risk of day 7 infection (17.3% cf. 7.4%: P = 0.006; OR 2.60) and AKI (20.8% cf. 7.0%: P = 0.008; OR 3.46) if the NLR was > 8. Incorporation of NLR into a modified Glasgow alcoholic hepatitis score (mGAHS) improved the AUC to 0.783 and 0.739 for 28‐day and 90‐day outcome, respectively. Conclusion: The NLR is associated with AKI and infection in severe alcoholic hepatitis. The NLR identifies those most likely to benefit from corticosteroids at baseline (NLR 5‐8). The mGAHS has a good predictive value for 28‐ and 90‐day outcomes. Linked Content This article is linked to Abdallah and Singal paper. To view this article, visit https://doi.org/10.1111/apt.15399. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

45. Public Health Response to HIV Epidemics among Injecting Drug Users in South Asia: A Systematic Review.

Author

Nazar, Chaudhary Muhammad Junaid, Ahtizaz Ahmad, Syed Muhammad, Izhar, Saba, and Katarey, Dev

Subjects
NEEDLE exchange programs, HARM reduction, INTRAVENOUS anesthesia, INTRAVENOUS drug abusers, HEALTH facilities, MEDICAL screening, HEALTH policy
Abstract

BACKGROUND: World Health Organization (WHO) has defined harm reduction (HR) programs specifically in relation to injection drug users (IDUs) which states that the comprehensive intervention included in HR package aims to prevent the propagation of blood borne infections including HIV that occurs through sharing of contaminated injecting equipment and drug preparations. In the present systematic review, we aim to describe HR programs targeted towards IDUs in South Asia (SA) and to explore the trend of HIV infection and risk behaviors among IDUs in these countries. METHODS: Online search was done using electronic databases including PubMed (Medline), Psychinfo, SCIRUS Studies (Elsevier and Google Scholar). Studies that described HR program, HIV infection and risk behaviors among IDUs were included in the review. The authors selected the original articles in English language, extracted the data and performed narrative analyses based on WHO's comprehensive intervention criteria evaluating the prevention and treatment of HIV among IDUs. RESULTS: Search resulted in 76 peer reviewed and 78 grey literature manuscripts from 1991 to 2010. HIV among IDUs has been reported in all countries of SA except in Bhutan and Maldives. The problem is concentrated (>5%) in India, Nepal and Pakistan. HR interventions are implemented in all countries where HIV among IDUs exists, but the coverage is low. The access of IDUs to the HR program ranged from 17% in Afghanistan to 50% in India. None of the countries had all elements of the WHO's comprehensive intervention package. Considerable decline in HIV prevalence and risk behaviors among IDUs is observed in Nepal and India (north-eastern states). The initiation of HR program in Bangladesh has maintained low HIV prevalence among IDUs, but HIV prevalence in Pakistan and other areas of India continues to increase. CONCLUSION: Decrease in risk behaviors and HIV prevalence among IDUs have been found in areas with good coverage of HR program. Hence, the SA countries should continue HR interventions with emphasis on increasing the comprehensive coverage. However, the inconsistent results from the region and the lack of effectiveness studies makes it difficult to reach a general conclusion about the role of HR program in reducing HIV infection and risk behaviors among IDUs in SA. Therefore, there is a need for effectiveness studies of available HR programs in SA. [ABSTRACT FROM AUTHOR]

Published
2014

48. Is the PBL generation of medical students reliant on Dr Google?

Author

Naeem, Mahum and Katarey, Dev

Subjects
*PROFESSIONAL education, *ADULTS, *LEARNING strategies, *MEDICAL students, *ONLINE information services, *SEARCH engines, STUDY & teaching of medicine
Abstract

A letter to the editor is presented in response to the article "Should we choose between problem-based learning and team-based learning? No, combine the best of both worlds!" by D. Dolmans, L. Michaelson, J. van Merriënboer, and C. van der Vleuten, which appeared in a 2015 issue of the journal.

Published
2016
Full Text
View/download PDF

50. Location and allocation: Inequity of access to liver transplantation for patients with severe acute-on-chronic liver failure in Europe.

Author

Artzner T, Bernal W, Belli LS, Conti S, Cortesi PA, Sacleux SC, Pageaux GP, Radenne S, Trebicka J, Fernandez J, Perricone G, Piano S, Nadalin S, Morelli MC, Martini S, Polak WG, Zieniewicz K, Toso C, Berenguer M, Iegri C, Invernizzi F, Volpes R, Karam V, Adam R, Faitot F, Rabinowich L, Saliba F, Meunier L, Lesurtel M, Uschner FE, Michard B, Coilly A, Meszaros M, Poinsot D, Besch C, Schnitzbauer A, De Carlis LG, Fumagalli R, Angeli P, Arroyo V, Fondevila C, Duvoux C, Jalan R, Belli LS, Perricone G, Viganò R, Mazzarelli C, De Carlis LG, Lauterio A, Giacomoni A, Invernizzi F, Donato F, Lampertico P, Iegri C, Pasulo L, Fagiuoli S, Colledan M, Morelli MC, Vitale G, Martini S, Ottobrelli A, Patrono D, Romagnoli R, Volpes R, Petridis I, Piano S, Angeli P, Cillo U, Germani G, Burra P, Bachellier P, Schneider F, Castelain V, Addeo P, Deridder M, Coilly SCSA, Faouzi S, Adam R, Samuel D, Duvoux C, Radenne S, Lesurtel M, Poinsot D, Guichon C, Pageaux GP, Faure S, Meszaros M, Meunier L, Ursic-Bedoya J, Fondevila C, Colmenero J, Toapanta D, Hernández-Tejero M, Berenguer M, Vinaixa C, Polak WG, den Hoed C, de Haan JE, Nadalin S, Penna AD, Uschner FE, Welker M, Schnitzbauer A, Zeuzem S, Bechstein W, Trebicka J, Toso C, Goossens N, Raszeja-Wyszomirska J, Zieniewicz K, Bernal W, Rabinovich L, Katarey D, Agarwal B, and Jalan R

Subjects
Humans, Intensive Care Units, Liver Cirrhosis, Prognosis, Retrospective Studies, Treatment Outcome, Waiting Lists, Acute-On-Chronic Liver Failure diagnosis, Acute-On-Chronic Liver Failure surgery, Liver Transplantation adverse effects
Abstract

There is growing evidence that liver transplantation (LT) is the most effective treatment for acute-on-chronic liver failure grade-3 (ACLF-3). This study examines whether and how this evidence translates into practice by analyzing the variability in intensive care unit (ICU) admissions, listing strategies, and LT activity for patients with ACLF-3 across transplantation centers in Europe. Consecutive patients who were admitted to the ICU with ACLF-3, whether or not they were listed and/or transplanted with ACLF-3, between 2018 and 2019 were included across 20 transplantation centers. A total of 351 patients with ACLF-3 were included: 33 had been listed prior to developing ACLF-3 and 318 had not been listed at the time of admission to the ICU. There was no correlation between the number of unlisted patients with ACLF-3 admitted to the ICU and the number listed or transplanted while in ACLF-3 across centers. By contrast, there was a correlation between the number of patients listed and the number transplanted while in ACLF-3. About 21% of patients who were listed while in ACLF-3 died on the waiting list or were delisted. The percentage of LT for patients with ACLF-3 varied from 0% to 29% for those transplanted with decompensated cirrhosis across centers (average = 8%), with an I 2 index of 68% (95% confidence interval, 49%-80%), showing substantial heterogeneity among centers. The 1-year survival for all patients with ACLF-3 was significantly higher in centers that listed and transplanted more patients with ACLF-3 (>10 patients) than in centers that listed and transplanted fewer: 36% versus 20%, respectively (p = 0.012). Patients with ACLF-3 face inequity of access to LT across Europe. Waitlisting strategies for patients with ACLF-3 influence their access to LT and, ultimately, their survival., (© 2022 American Association for the Study of Liver Diseases.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results